the core of our corporate values
On April12, Zylox-Tonbridge (2190.HK, “the Company”) announced its PTA Balloon Catheter-Large Diameter, a product independently developed by the Company, has been granted the marketing approval by t...
Zylox-Tonbridge (2190.HK, hereinafter called the Company) announced on March 15 its first fiscal-year financial report since its IPO on Hong Kong Stock Exchange.The Company reported an ope...
Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge" or "the Company", "2190.HK") announced on February 28 that it has received approval from Hong Kong Stock E...
On January 17, Zylox-Tonbridge (2190.HK, “the Company”) announced the completion of its strategic investment in Wire Sciences Medical Technology(Suzhou)Co., Ltd. (“Wire Sciences”). By leveraging its own s...
On December 13, Zylox-Tonbridge's postdoctoral workstation in cooperation with Zhejiang University (hereinafter referred to as "postdoctoral workstation”) was officially inaugurated.On the s...
Hangzhou, China, 29 November 2021- Zylox-Tonbridge (2190.HK, the “Company”) announced the last patient enrollment was completed for the clinical trial of “Tonbridge KylinTM” Flow Diverter (single ...